Novel Polymers for Cell Encapsulation

描述（由申请人提供）：全球成人糖尿病的发病率呈上升趋势，构成了一个主要的健康问题。我们建议开发一种新的胶囊化葡萄糖响应性胰岛素分泌细胞植入物，用于治疗I型糖尿病，使用聚（γ-谷氨酸）（γ-PGA）。以前没有，非常高的分子量γ-PGA将使用专有工艺制备。初步研究的初步数据表明，γ-PGA构成了一种有前途的材料和可行的方法，用于治疗用途中的有效和延长的胰岛素输送。 拟议的商业应用： 糖尿病是一个主要的健康问题。糖尿病可导致许多并发症，例如，下肢溃疡、视觉功能障碍和伤口愈合受损。大约90%的糖尿病治疗费用都花在了糖尿病沟通上。仅终末期肾病治疗就花费了超过110亿美元。胰岛素-PGA输送系统的成功开发将对糖尿病治疗产生重大影响。实现生物相容性PGA细胞封装的制备将构成生物聚合物使用的一个重要里程碑。

DESCRIPTION (provided by applicant): The incidence of diabetes mellitus in adults is on the rise globally and constitutes a major health problem. We are proposing the development of a new encapsulated glucose-responsive insulin secreting cell implants for the treatment of type I diabetes, using poly(gamma-glutamic acid) (gamma-PGA). Previously unavailable, very high molecular weight gamma-PGA will be prepared, using a proprietary process. Preliminary data from pilot studies indicate that gamma-PGA constitutes a promising material and viable approach for efficacious and prolonged insulin delivery in therapeutic uses. PROPOSED COMMERCIAL APPLICATIONS: Diabetes mellitus constitutes a major health problem. Diabetes can lead to many complications, e.g., lower extremity ulcers, visual dysfunctions, and impaired wound healing. About 90% of the costs of diabetes therapy are spent on diabetes communications. Over $11 billion is spend on end-stage renal disease treatment alone. Successful development of insulin-PGA delivery systems will have a major impact on diabetes therapy. Achieving the preparation of biocompatible PGA for cell encapsulation will constitute a major milestone in the use of biopolymers.